Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › PCVX

SILVERARC CAPITAL MANAGEMENT, LLC position in PCVX

VAXCYTE INC · Health Care

SILVERARC CAPITAL MANAGEMENT, LLC reported holding 125,080 shares of PCVX (VAXCYTE INC) in its Q3 2026 13F filing — a position valued at US$7.1M, representing 0.91% of its reported portfolio and ranking #30 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed PCVX holdings in 9 of the last 10 reported quarters, going back to Q2 2024.

Latest position (Q3 2026)125.08K sh
Reported value held$7.12M
Portfolio Weight0.91%
First reportedQ2 2024
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How SILVERARC CAPITAL MANAGEMENT, LLC's PCVX position evolved

SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in PCVX in Q2 2024 at 2,500 shares (US$189K). The position peaked in Q3 2025 at 314,339 shares, worth US$11.3M. Across 9 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 2 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 125,080 shares valued at US$7.1M — a reduction of -19,920 shares quarter over quarter.. Notable position changes include a 2320% increase in Q3 2024 (shares fell 28% over the following quarter), a 33% trim in Q4 2024 (shares fell 54% over the following quarter), a 53% trim in Q4 2025 (shares rose 26% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q2 2024 2.50K $188.78K New
Q3 2024 60.50K $6.91M Add
Q4 2024 40.79K $3.34M Reduce
Q2 2025 287.80K $9.36M New
Q3 2025 314.34K $11.32M Add
Q4 2025 148.79K $6.87M Reduce
Q1 2026 144.98K $8.42M Reduce
Q2 2026 145.00K $8.43M Hold
Q3 2026 125.08K $7.12M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PCVX and 13F data

PCVX (VAXCYTE INC) is a Health Care company. 33 other funds we track also report a position in PCVX — the largest reported positions include Jupiter Topco LLC (US$1.04B), Janus Henderson Group (US$960.2M), T. Rowe Price Investment Management, Inc. (US$709.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PCVX

All PCVX fund holders →

FAQ

How long has SILVERARC CAPITAL MANAGEMENT, LLC held PCVX?

SILVERARC CAPITAL MANAGEMENT, LLC has disclosed PCVX holdings in 9 of the last 10 reported quarters, going back to Q2 2024.

What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in PCVX?

As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 125.08K shares of PCVX (VAXCYTE INC), valued at $7.12M, representing 0.91% of its reported portfolio and ranking #30.

Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling PCVX?

In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC reduced its position in PCVX. The position peaked in Q3 2025 at 314.34K shares.

Which other funds hold PCVX?

Other major institutional holders of PCVX include Jupiter Topco LLC, Janus Henderson Group, T. Rowe Price Investment Management, Inc., among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.